Current guidelines for thienopyridines in PCI note the lack of RCT data for higher loading doses. Read Dr Wang's lowdown on loading doses, including recent presentations from the 2008 SCAI-ACCi2 meeting. Then watch Drs Mehta and Mehran discuss where CURRENT-OASIS-7 will fit in.
Balancing antithrombotic efficacy with risk of bleeding: Join our international panel of experts, Steen Husted, José Carlos Nicolau, Sunil Rao and Robert Storey as they review the mechanisms of platelet activation and emerging evidence from ongoing studies to novel antiplatelet therapies.
If we're all looking at the same data, why do the European and US guidelines for the treatment of ACS differ in terms of initiation, dosing, and choices of pharmacological therapies? Drs Ohman, Montalescot, Pollack and Fox discuss the similarities and differences.
As continued refinements in catheter-based device technology continue to occur, further increases in the number of interventional procedures will likely result. Despite the demonstrated clinical benefit of reperfusion strategies, substantial challenges exist in identifying the precise combination of therapeutic agents and interventional procedures that will maximize patient outcomes. In addition, intra-procedural complications occur and remain an important source of patient morbidity and mortality. Through a combination of lectures, case-based discussions, and audience interaction this activity will address the complexities of acute STEMI management, available reperfusion strategies, challenges to minimizing intra-procedural complications, and overall strategies to optimize patient outcomes. The faculty will discuss unique clinical challenges while emphasizing evidence-based treatment strategies.
Despite advances in the standard of care for high-risk patients with acute coronary syndrome (ACS) and evidence-based guidelines recommending antiplatelet agents as the cornerstone of therapy, existing therapies still have considerable limitations. Currently, dual therapy with aspirin and a thienopyridine is the standard of care, but new combinations of antiplatelet agents and new drugs with potent antiplatelet effects, such as AZD6140, cangrelor, and prasugrel, have been evaluated in clinical trials, and these agents may ultimately improve outcomes in patients with ACS. This unique educational symposium will feature an expert faculty leading a highly engaging discussion with the audience on many controversial topics concerning the use of antiplatelet agents in the care of patients with ACS.
Drs Moliterno, Gurbel, Gurm and Pollack will challenge you to reconsider established strategies for treating ACS and will assess the significance of the latest developments.
What is the optimal pharmacological management of STEMI? Please join Dr Michael Gibson as he explores recent clinical trial data, including FINESSE, HORIZONS AMI and EXPIRA.
